https://orcid.org/0000-0002-7806-9986
References
- Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.
- Ahmed A, JO C. In: Proton Pump Inhibitors (PPI). 2022. Treasure Island (FL): StatPearls. NCBI Bookshelf. Bookshelf ID NBK557385
- Al-Aly Z, Maddukuri G, Xie Y. Proton pump inhibitors and the kidney: implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis. 2020;75(4):497–507.
- Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070–1086.
- Guideline on good pharmacovigilance practices (GVP) Module IX-Signal management (Rev 1); EMA and heads of medicines agency. Available from: https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/signal-management.
- Lerch M, Nowicki P, Malik K, et al. Statistical signal detection as a routine pharmacovigilance practice: effects of periodicity and resignalling criteria on quality and workload. DrugSaf. 2015;38(12):1219–1231.
- Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179.
- Chen G, Ning LJ, Qin Y, et al. Acute kidney injury following the use of different proton pump inhibitor regimens: a real-world analysis of post-marketing surveillance data. J Gastroenterol Hepatol. 2021;36(1):156–162.
- Eltriki MB, Green CJ, Maclure M, et al. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect. 2020;8:5.
- Hart E, Dunn TE, Feuerstein S, et al. Proton pump inhibitors and risk of acute and chronic kidney disease: a retrospective cohort study. Pharmacotherapy. 2019;39(4):443–453.
- Carnovale C, Gentili M, Mazhar F, et al. A characterization and disproportionality analysis of medication error-related adverse events reported to the FAERS database. Expert Opin Drug Saf. 2018;17(12):1161–1169.
- Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 2001;10(6):483–486.
- Härmark L, Van Der Wiel HE, De Groot MC, et al. Proton pump inhibitor‐induced acute interstitial nephritis. Br J Clin Pharmacol. 2007;64(6):819–823.
- Rubin S, Orieux A, Clouzeau B, et al. The incidence of chronic kidney disease three years after non-severe acute kidney injury in critically ill patients: a single-center cohort study. J Clin Med. 2019 Dec 14;8(12):2215. PMID: 31847384; PMCID: PMC6947258
- Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442–448. Epub 2011 Nov 23. PMID: 22113526; PMCID: PMC3788581
- Chawla LS, Amdur RL, Shaw AD, et al. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. 2014 Mar 9;9(3):448–456. Epub 2013 Dec 5. PMID: 24311708; PMCID: PMC3944753
- Abassi Z, Shalabi A, Sohotnik R, et al. NGAL and KIM-1: biomarkers for assessment of acute ischemic kidney injury following nephron sparing surgery. J Urol. 2013 Apr;189(4):1559–1566. Epub 2012 Oct 22. PMID: 23085062
- Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005 Apr 2-8;365(9466):1231–1238. PMID: 15811456
- Hosohata K. Role of oxidative stress in drug-induced kidney injury. Int J Mol Sci. 2016 Nov 1;17(11):1826. PMID: 27809280; PMCID: PMC5133827
- Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2017;176(2):238–246.
- Wu B, Hu Q, Tian F, et al. A pharmacovigilance study of the association between proton pump inhibitor and dementia event based on FDA adverse event reporting system data. Sci Rep. 2021;11(1):10709.
- Xie Y, Bowe B, Li T, et al. Long term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91(6):1482–1494.
- Vengrus CS, Delfino VD, Bignardi PR. Proton pump inhibitors use and risk of chronic kidney disease and end-stage renal disease. Minerva Urology and Nephrology. 2021;73(4):462–470.
- Sun J, Sun H, Cui M, et al. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis. Int. Urol Nephrol. 2018;50(10):1835–1843.
- Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2018;33(2):331–342.